INHBA and colon adenocarcinoma: In future clinical treatments, we can use the risk score model to effectively predict the survival prognosis of patients with COAD, and we can do targeted immunotherapy for 7 immune genes (SLC10A2, CXCL3, IGHV5-51, INHBA, STC1, UCN, and OXTR) that constitute the risk score to improve the prognosis of patients and improve the treatment effect.